Skip to main content

Table 2 Demographic and Clinicopathologic Factors in Melanoma Patients Undergoing Inguino-femoral Lymph Node Dissection (ILND)

From: Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT00506311)

 

Fibrin sealant group,n = 16

Control group,n = 14

 

Variable

No.a

% of total

No.a

% of total

P value

Median age, years (range)

52 (38–91)

 

60 (18–73)

 

0.79

Sex, male/female

12/4

75/25

7/7

50/50

0.16

Median BMI, kg/m2 (range)

28.3 (19.6–42.1)

 

32.3 (21–48.6)

 

0.15

Comorbidities

     

   Tobacco use

1

6

2

14

0.58

   Diabetes

1

6

4

29

0.16

AJCC tumor stage

    

1.00

   III

14

88

13

93

 

   IV

2

12

1

7

 

Melanoma treatment prior to ILND

     

   Surgery

    

0.34

None/FNA

5

31

4

29

 

SLN biopsy

6

38

8

57

 

Excisional biopsy/WLE

5

31

2

14

 

   Systemic therapy

    

0.27

Chemotherapy

2

12

0

 

0.48

Interferon

1

6

2

14

0.59

Interleukin-2

1

6

0

 

1.00

  1. BMI, body mass index; AJCC, American Joint Committee on Cancer; FNA, fine needle aspiration; SLN, sentinel lymph node; WLE, wide local excision.
  2. aData are number of patients unless otherwise indicated.